RxDoctor Payments Data

Andrew Dockter, MD

Family Medicine · Mandan, NDNPI 1255851077

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations.

$983in general payments, 2019–2025

Across 52 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$231
  • Amgen$191
  • Acell, Inc.$120
  • Astellas Pharma US Inc$94
  • E.r. Squibb & Sons, L.L.C.$76
  • Xeris Pharmaceuticals, Inc.$38
  • plus $234 from 11 others

What the payments were for

  • Food & beverage$983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$983 in reported general payments places this provider in the 80th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$62,728
Medicare patients
276
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$86,815
EliquisApixaban70$66,837
OzempicSemaglutide25$35,017
MounjaroTirzepatide28$28,293
FarxigaDapagliflozin Propanediol32$21,150
RybelsusSemaglutide11$20,685
XareltoRivaroxaban21$19,636
TrulicityDulaglutide17$15,864
Tresiba Flextouch U-200Insulin Degludec14$12,494
Spiriva RespimatTiotropium Bromide21$11,474
DuleraMometasone/Formoterol12$4,405
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,223
Metoprolol Succinate193$3,759
Atorvastatin Calcium306$3,704
Rosuvastatin Calcium227$3,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$21$98,288129 claims
PfizerEliquis$14$66,83770 claims
Lilly USA, LLCMounjaro, Trulicity$37$44,15745 claims
MerckDulera$19$4,40512 claims
AbbVieSynthroid$231$1,59622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Mandan

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →